Anakinra and rilonacept: evidence-based for refractory recurrent pericarditis
Pericardiocentesis technique considerations
Echocardiographic guidance preferred
Reduces complication rate compared to blind technique
Real-time needle visualization preferred over static guidance
Contrast injection through needle verifies pericardial vs. ventricular position
Post-drainage drain placement reduces recurrence
Surgical options
Pericardial window: for recurrent or malignant effusions
Subxiphoid approach: preferred for frail or high-risk patients
Video-assisted thoracoscopic (VATS) pericardiectomy: alternative
Pericardiectomy: for constrictive pericarditis
Monitoring strategy
CRP normalization as treatment endpoint
Guides duration and discontinuation of anti-inflammatory therapy
Serial echocardiography for effusion size tracking
Repeat within 1 week for moderate-to-large effusions
Patient Discharge Instructions
copy discharge instructions
Diagnosis and what it means
Pericardial effusion: fluid collected around your heart
Can be caused by infection, inflammation, autoimmune disease, or other conditions
Most small-to-moderate effusions improve with medication and time
Medications at home
Take your anti-inflammatory medication exactly as prescribed
Ibuprofen or aspirin: take with food to reduce stomach irritation
Do not stop early even if you feel better
Colchicine: take every day for the full prescribed course
Stopping early greatly increases the chance of your effusion and inflammation returning
Take the stomach-protecting medication (PPI) with your anti-inflammatory
Activity restrictions
No strenuous physical activity, heavy lifting, or vigorous exercise for at least 1 month
Keep your heart rate below 100 beats per minute during this period
Light walking is acceptable
No competitive sports until cleared by your cardiologist
Follow-up appointments
Cardiology follow-up within 1–2 weeks of discharge
Repeat echocardiogram (heart ultrasound) within 1 week as arranged
Blood test (CRP) monitoring to ensure inflammation is resolving
Return to emergency department immediately if
Worsening shortness of breath or new inability to lie flat
Lightheadedness, dizziness, or fainting
Worsening chest pain
Rapid or irregular heart rate
Swelling in legs or abdomen
New fever or chills
Lifestyle guidance
Avoid alcohol during treatment with NSAIDs: increases stomach bleeding risk
Adequate hydration: do not become dehydrated
Sodium restriction if your doctor has told you to limit salt (especially if heart failure present)
Recurrence awareness
15–30% of patients experience a second episode after first pericarditis
Risk decreases significantly with completion of full colchicine course
Report any return of chest pain, fever, or shortness of breath promptly
References
Guidelines and key sources
ACC 2025 Expert Consensus Statement on Pericarditis
Wang TKM, Klein AL, Cremer PC, et al. 2025 Concise Clinical Guidance: ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis. Journal of the American College of Cardiology. 2025
Primary evidence source for risk stratification, treatment algorithms, and colchicine duration
JAMA Review 2024
Cremer PC, Klein AL, Imazio M. Diagnosis, Risk Stratification, and Treatment of Pericarditis: A Review. JAMA. 2024
Key epidemiologic statistics and treatment evidence synthesis
JACC Cardiovascular Imaging 2024
Klein AL, Wang TKM, Cremer PC, et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC Cardiovascular Imaging. 2024
Multimodality imaging protocols for echocardiography, CT, and MRI
Landmark trials
COPE Trial
Imazio M, et al. Colchicine for Recurrent Pericarditis. Circulation. 2005
Colchicine reduced recurrence by 50% in first acute episode
ICAP Trial
Imazio M, et al. A Randomized Trial of Colchicine for Acute Pericarditis. NEJM. 2013
Confirmed colchicine benefit as adjunct to aspirin: NNT 8 to prevent one recurrence
AIRTRIP Trial
Imazio M, et al. Anakinra for Corticosteroid-Dependent and Colchicine-Resistant Pericarditis. Heart. 2016
Anakinra reduced recurrence in refractory inflammatory pericarditis
RHAPSODY Trial
Klein AL, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. NEJM. 2021
Rilonacept reduced recurrence by 96% vs. placebo; FDA approval basis
Additional references
Cardiac tamponade review
Adler Y, Ristic AD, Imazio M, et al. Cardiac Tamponade. Nature Reviews Disease Primers. 2023
Spodick DH. Acute Cardiac Tamponade. NEJM. 2003
Chronic pericardial effusion management
Lazaros G, Imazio M, Tsioufis P, et al. Chronic Pericardial Effusion: Causes and Management. Canadian Journal of Cardiology. 2023
Imazio M, Adler Y. Management of Pericardial Effusion. European Heart Journal. 2013
ECG in pericardial effusion
Eisenberg MJ, et al. The Diagnosis of Pericardial Effusion and Cardiac Tamponade by 12-Lead ECG. Chest. 1996
Longo MJ, Jaffe CC. Electrical Alternans. NEJM. 1999
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.